| Variable . | Success . | Nonsuccess . | Proportion With Success, . | P Value . |
|---|---|---|---|---|
| (n = 105) . | (n = 19) . | n/N (%) . | ||
| Age ≥65 y | 42 (40.0) | 6 (31.6) | 42/48 (87.5) | .595 |
| Gender | ||||
| Male | 58 (55.2) | 15 (78.9) | 58/73 (79.4) | .053 |
| Female | 47 (44.8) | 4 (21.0) | 47/51 (92.2) | .053 |
| Location before C/T | ||||
| Community | 61 (58.1) | 8 (42.1) | 61/69 (88.4) | .197 |
| Hospital | 44 (41.9) | 11 (57.9) | 44/55 (80.0) | .197 |
| Charlson comorbidity index, median (range) | 4.0 (0–8.0) | 5.0 (3.5–6.5) | … | .922 |
| BMI ≥30 kg/m2 | 43 (40.9) | 11 (57.9) | 43/54 (79.6) | .171 |
| Renal function (CrCl) | ||||
| Normal (>90 mL/min) | 55 (52.4) | 13 (68.4) | 55/68 (80.9) | .196 |
| Mild (51–90 mL/min) | 33 (31.4) | 6 (31.6) | 33/39 (84.6) | .989 |
| Moderate (30–50 mL/min) | 12 (11.4) | 0 | 12/12 (100) | .121 |
| Severe (<30 mL/min) | 3 (2.9) | 0 | 3/3 (100) | .456 |
| Comorbidities | ||||
| Cardiovascular disease | 72 (68.6) | 11 (57.9) | 72/83 (86.7) | .363 |
| Diabetes mellitus | 37 (35.2) | 11 (57.9) | 37/48 (77.1) | .062 |
| Immunocompromised | 41 (39.0) | 7 (36.8) | 41/48 (85.4) | .856 |
| Malignancy (current) | 24 (22.9) | 4 (21.0) | 24/28 (85.7) | .862 |
| Chronic kidney disease | 14 (13.3) | 1 (5.3) | 14/15 (93.3) | .321 |
| Liver disease | 5 (4.8) | 3 (15.8) | 5/8 (62.5) | .071 |
| Infection type | ||||
| Bone and joint | 24 (22.9) | 9 (47.4) | 24/33 (72.7) | .026 |
| Urinary tract | 28 (26.7) | 1 (5.3) | 28/29 (96.6) | .042 |
| Respiratory tract | 21 (20.0) | 1 (5.3) | 21/22 (95.4) | .121 |
| Intra-abdominal | 16 (15.2) | 4 (21.0) | 16/20 (80.0) | .526 |
| Skin and soft tissue | 14 (13.3) | 3 (15.8) | 14/17 (82.4) | .774 |
| Bacteremia | 2 (1.9) | 1 (5.3) | 2/3 (66.7) | .380 |
| Concurrent bacteremia | 9 (7.6) | 3 (15.8) | 9/12 (75.0) | .249 |
| Causative pathogen | ||||
| P. aeruginosa infection | 67 (63.8) | 11 (57.9) | 67/78 (85.9) | .696 |
| MDR | 43 (40.9) | 7 (36.8) | 43/50 (86.0) | 1.000 |
| CR | 27 (25.7) | 7 (36.8) | 27/34 (79.4) | .195 |
| Enterobacterales infection | 18 (17.1) | 4 (21.0) | 18/22 (81.8) | .683 |
| ESBL | 10 (9.5) | 1 (5.3) | 10/11 (90.9) | .586 |
| Variable . | Success . | Nonsuccess . | Proportion With Success, . | P Value . |
|---|---|---|---|---|
| (n = 105) . | (n = 19) . | n/N (%) . | ||
| Age ≥65 y | 42 (40.0) | 6 (31.6) | 42/48 (87.5) | .595 |
| Gender | ||||
| Male | 58 (55.2) | 15 (78.9) | 58/73 (79.4) | .053 |
| Female | 47 (44.8) | 4 (21.0) | 47/51 (92.2) | .053 |
| Location before C/T | ||||
| Community | 61 (58.1) | 8 (42.1) | 61/69 (88.4) | .197 |
| Hospital | 44 (41.9) | 11 (57.9) | 44/55 (80.0) | .197 |
| Charlson comorbidity index, median (range) | 4.0 (0–8.0) | 5.0 (3.5–6.5) | … | .922 |
| BMI ≥30 kg/m2 | 43 (40.9) | 11 (57.9) | 43/54 (79.6) | .171 |
| Renal function (CrCl) | ||||
| Normal (>90 mL/min) | 55 (52.4) | 13 (68.4) | 55/68 (80.9) | .196 |
| Mild (51–90 mL/min) | 33 (31.4) | 6 (31.6) | 33/39 (84.6) | .989 |
| Moderate (30–50 mL/min) | 12 (11.4) | 0 | 12/12 (100) | .121 |
| Severe (<30 mL/min) | 3 (2.9) | 0 | 3/3 (100) | .456 |
| Comorbidities | ||||
| Cardiovascular disease | 72 (68.6) | 11 (57.9) | 72/83 (86.7) | .363 |
| Diabetes mellitus | 37 (35.2) | 11 (57.9) | 37/48 (77.1) | .062 |
| Immunocompromised | 41 (39.0) | 7 (36.8) | 41/48 (85.4) | .856 |
| Malignancy (current) | 24 (22.9) | 4 (21.0) | 24/28 (85.7) | .862 |
| Chronic kidney disease | 14 (13.3) | 1 (5.3) | 14/15 (93.3) | .321 |
| Liver disease | 5 (4.8) | 3 (15.8) | 5/8 (62.5) | .071 |
| Infection type | ||||
| Bone and joint | 24 (22.9) | 9 (47.4) | 24/33 (72.7) | .026 |
| Urinary tract | 28 (26.7) | 1 (5.3) | 28/29 (96.6) | .042 |
| Respiratory tract | 21 (20.0) | 1 (5.3) | 21/22 (95.4) | .121 |
| Intra-abdominal | 16 (15.2) | 4 (21.0) | 16/20 (80.0) | .526 |
| Skin and soft tissue | 14 (13.3) | 3 (15.8) | 14/17 (82.4) | .774 |
| Bacteremia | 2 (1.9) | 1 (5.3) | 2/3 (66.7) | .380 |
| Concurrent bacteremia | 9 (7.6) | 3 (15.8) | 9/12 (75.0) | .249 |
| Causative pathogen | ||||
| P. aeruginosa infection | 67 (63.8) | 11 (57.9) | 67/78 (85.9) | .696 |
| MDR | 43 (40.9) | 7 (36.8) | 43/50 (86.0) | 1.000 |
| CR | 27 (25.7) | 7 (36.8) | 27/34 (79.4) | .195 |
| Enterobacterales infection | 18 (17.1) | 4 (21.0) | 18/22 (81.8) | .683 |
| ESBL | 10 (9.5) | 1 (5.3) | 10/11 (90.9) | .586 |
Abbreviations: BMI, body mass index; CR, carbapenem-resistant; C/T, ceftolozane/tazobactam; ESBL, extended-spectrum beta-lactamase; MDR, multidrug-resistant; OIC, office infusion center.
All values represent number of patients (%) unless otherwise indicated.
Chi-square test or Fisher exact test was used for categorical variables, and Wilcoxon rank test for continues variables.
Due to immunosuppressive medication (chemotherapy, steroids, biologics) or underlying immune deficiency (cancer, AIDS, genetic disorder, autoimmune disease, organ transplant, CKD).
Including E. coli (n = 14), Klebsiella spp. (n = 4), Enterobacter cloacae (n = 3), Citrobacter koseri (n = 1).
Bivariate analysis indicated that patients with bone and joint infections were less likely to experience success compared with patients treated with ceftolozane/tazobactam for other infection types (72.7% vs 89.0%; P = .026).
Bivariate analysis indicated that patients with urinary tract infection were more likely to experience success compared with patients treated with ceftolozane/tazobactam for other infection types (96.6% vs 81.0%; P = .042).
| Variable . | Success . | Nonsuccess . | Proportion With Success, . | P Value . |
|---|---|---|---|---|
| (n = 105) . | (n = 19) . | n/N (%) . | ||
| Age ≥65 y | 42 (40.0) | 6 (31.6) | 42/48 (87.5) | .595 |
| Gender | ||||
| Male | 58 (55.2) | 15 (78.9) | 58/73 (79.4) | .053 |
| Female | 47 (44.8) | 4 (21.0) | 47/51 (92.2) | .053 |
| Location before C/T | ||||
| Community | 61 (58.1) | 8 (42.1) | 61/69 (88.4) | .197 |
| Hospital | 44 (41.9) | 11 (57.9) | 44/55 (80.0) | .197 |
| Charlson comorbidity index, median (range) | 4.0 (0–8.0) | 5.0 (3.5–6.5) | … | .922 |
| BMI ≥30 kg/m2 | 43 (40.9) | 11 (57.9) | 43/54 (79.6) | .171 |
| Renal function (CrCl) | ||||
| Normal (>90 mL/min) | 55 (52.4) | 13 (68.4) | 55/68 (80.9) | .196 |
| Mild (51–90 mL/min) | 33 (31.4) | 6 (31.6) | 33/39 (84.6) | .989 |
| Moderate (30–50 mL/min) | 12 (11.4) | 0 | 12/12 (100) | .121 |
| Severe (<30 mL/min) | 3 (2.9) | 0 | 3/3 (100) | .456 |
| Comorbidities | ||||
| Cardiovascular disease | 72 (68.6) | 11 (57.9) | 72/83 (86.7) | .363 |
| Diabetes mellitus | 37 (35.2) | 11 (57.9) | 37/48 (77.1) | .062 |
| Immunocompromised | 41 (39.0) | 7 (36.8) | 41/48 (85.4) | .856 |
| Malignancy (current) | 24 (22.9) | 4 (21.0) | 24/28 (85.7) | .862 |
| Chronic kidney disease | 14 (13.3) | 1 (5.3) | 14/15 (93.3) | .321 |
| Liver disease | 5 (4.8) | 3 (15.8) | 5/8 (62.5) | .071 |
| Infection type | ||||
| Bone and joint | 24 (22.9) | 9 (47.4) | 24/33 (72.7) | .026 |
| Urinary tract | 28 (26.7) | 1 (5.3) | 28/29 (96.6) | .042 |
| Respiratory tract | 21 (20.0) | 1 (5.3) | 21/22 (95.4) | .121 |
| Intra-abdominal | 16 (15.2) | 4 (21.0) | 16/20 (80.0) | .526 |
| Skin and soft tissue | 14 (13.3) | 3 (15.8) | 14/17 (82.4) | .774 |
| Bacteremia | 2 (1.9) | 1 (5.3) | 2/3 (66.7) | .380 |
| Concurrent bacteremia | 9 (7.6) | 3 (15.8) | 9/12 (75.0) | .249 |
| Causative pathogen | ||||
| P. aeruginosa infection | 67 (63.8) | 11 (57.9) | 67/78 (85.9) | .696 |
| MDR | 43 (40.9) | 7 (36.8) | 43/50 (86.0) | 1.000 |
| CR | 27 (25.7) | 7 (36.8) | 27/34 (79.4) | .195 |
| Enterobacterales infection | 18 (17.1) | 4 (21.0) | 18/22 (81.8) | .683 |
| ESBL | 10 (9.5) | 1 (5.3) | 10/11 (90.9) | .586 |
| Variable . | Success . | Nonsuccess . | Proportion With Success, . | P Value . |
|---|---|---|---|---|
| (n = 105) . | (n = 19) . | n/N (%) . | ||
| Age ≥65 y | 42 (40.0) | 6 (31.6) | 42/48 (87.5) | .595 |
| Gender | ||||
| Male | 58 (55.2) | 15 (78.9) | 58/73 (79.4) | .053 |
| Female | 47 (44.8) | 4 (21.0) | 47/51 (92.2) | .053 |
| Location before C/T | ||||
| Community | 61 (58.1) | 8 (42.1) | 61/69 (88.4) | .197 |
| Hospital | 44 (41.9) | 11 (57.9) | 44/55 (80.0) | .197 |
| Charlson comorbidity index, median (range) | 4.0 (0–8.0) | 5.0 (3.5–6.5) | … | .922 |
| BMI ≥30 kg/m2 | 43 (40.9) | 11 (57.9) | 43/54 (79.6) | .171 |
| Renal function (CrCl) | ||||
| Normal (>90 mL/min) | 55 (52.4) | 13 (68.4) | 55/68 (80.9) | .196 |
| Mild (51–90 mL/min) | 33 (31.4) | 6 (31.6) | 33/39 (84.6) | .989 |
| Moderate (30–50 mL/min) | 12 (11.4) | 0 | 12/12 (100) | .121 |
| Severe (<30 mL/min) | 3 (2.9) | 0 | 3/3 (100) | .456 |
| Comorbidities | ||||
| Cardiovascular disease | 72 (68.6) | 11 (57.9) | 72/83 (86.7) | .363 |
| Diabetes mellitus | 37 (35.2) | 11 (57.9) | 37/48 (77.1) | .062 |
| Immunocompromised | 41 (39.0) | 7 (36.8) | 41/48 (85.4) | .856 |
| Malignancy (current) | 24 (22.9) | 4 (21.0) | 24/28 (85.7) | .862 |
| Chronic kidney disease | 14 (13.3) | 1 (5.3) | 14/15 (93.3) | .321 |
| Liver disease | 5 (4.8) | 3 (15.8) | 5/8 (62.5) | .071 |
| Infection type | ||||
| Bone and joint | 24 (22.9) | 9 (47.4) | 24/33 (72.7) | .026 |
| Urinary tract | 28 (26.7) | 1 (5.3) | 28/29 (96.6) | .042 |
| Respiratory tract | 21 (20.0) | 1 (5.3) | 21/22 (95.4) | .121 |
| Intra-abdominal | 16 (15.2) | 4 (21.0) | 16/20 (80.0) | .526 |
| Skin and soft tissue | 14 (13.3) | 3 (15.8) | 14/17 (82.4) | .774 |
| Bacteremia | 2 (1.9) | 1 (5.3) | 2/3 (66.7) | .380 |
| Concurrent bacteremia | 9 (7.6) | 3 (15.8) | 9/12 (75.0) | .249 |
| Causative pathogen | ||||
| P. aeruginosa infection | 67 (63.8) | 11 (57.9) | 67/78 (85.9) | .696 |
| MDR | 43 (40.9) | 7 (36.8) | 43/50 (86.0) | 1.000 |
| CR | 27 (25.7) | 7 (36.8) | 27/34 (79.4) | .195 |
| Enterobacterales infection | 18 (17.1) | 4 (21.0) | 18/22 (81.8) | .683 |
| ESBL | 10 (9.5) | 1 (5.3) | 10/11 (90.9) | .586 |
Abbreviations: BMI, body mass index; CR, carbapenem-resistant; C/T, ceftolozane/tazobactam; ESBL, extended-spectrum beta-lactamase; MDR, multidrug-resistant; OIC, office infusion center.
All values represent number of patients (%) unless otherwise indicated.
Chi-square test or Fisher exact test was used for categorical variables, and Wilcoxon rank test for continues variables.
Due to immunosuppressive medication (chemotherapy, steroids, biologics) or underlying immune deficiency (cancer, AIDS, genetic disorder, autoimmune disease, organ transplant, CKD).
Including E. coli (n = 14), Klebsiella spp. (n = 4), Enterobacter cloacae (n = 3), Citrobacter koseri (n = 1).
Bivariate analysis indicated that patients with bone and joint infections were less likely to experience success compared with patients treated with ceftolozane/tazobactam for other infection types (72.7% vs 89.0%; P = .026).
Bivariate analysis indicated that patients with urinary tract infection were more likely to experience success compared with patients treated with ceftolozane/tazobactam for other infection types (96.6% vs 81.0%; P = .042).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
